Efficacy and Safety of F-18 FPCIT PET in Parkinson's Disease and Essential Tremor Patients (FPCIT)

January 11, 2016 updated by: Jae Seung Kim, Asan Medical Center

The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients

The purpose of this study is to determine whether F-18 FPCIT is effective and safe radiopharmaceutical for the objective diagnosis of Parkinson's disease.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Parkinson's disease is a common neurodegenerative disorder with loss of dopaminergic terminals in the striatum. Essential tremor is one of the conditions most commonly misdiagnosed as parkinsonism, and early clinical differentiation between these conditions can be difficult. F-18 FPCIT is a promising radiopharmaceutical for PET imaging to assess the dopamine transporter in the striatum.

Study Type

Interventional

Enrollment (Actual)

78

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

Parkinson's disease

  • Male or female with age over 40 years
  • Clinical diagnosis of Parkinson's disease
  • Ability to give informed consent

Essential tremor

  • Male or female with age over 40 years
  • Clinical diagnosis of Essential tremor
  • Ability to give informed consent

Healthy volunteers

  • Male or female with age over 40 years
  • No any symptoms or sign suggesting Parkinson's disease or essential tremor
  • Ability to give informed consent

Exclusion Criteria:

Parkinson's disease and essential tremor

  • Current pregnancy and breast feeding
  • Current or past medical history of cardiac and neuropsychiatric disease
  • Clinical evidence of dementia
  • Inability to hold antiparkinsonian medication
  • History of surgical therapy for tremor
  • Severe or unstable medical or psychiatric condition
  • Medication affecting CNS in last 6 months(e.g. CNS stimulants, sympathomimetics)
  • Prior participation in other research protocol within 30 days

Healthy volunteers

  • Current pregnancy and breast feeding
  • Current or past medical history of cardiac and neuropsychiatric disease
  • Severe or unstable medical or psychiatric condition
  • Drug abuse or medication affecting CNS (e.g. CNS stimulants, sympathomimetics) within 6 months
  • Prior participation in other research protocol within 30 days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: A
Parkinson's disease
Procedure: PET/CT
10min acquisition, 90min after injection of F-18 FPCIT
Other Names:
  • Positron Emission Tomography
Drug: F-18 FPCIT
5mCi, intravenous injection
Active Comparator: B
ET+Normal
Procedure: PET/CT
10min acquisition, 90min after injection of F-18 FPCIT
Other Names:
  • Positron Emission Tomography
Drug: F-18 FPCIT
5mCi, intravenous injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
diagnostic sensitivity and specificity, and acute complication
Time Frame: 1 month
1 month

Secondary Outcome Measures

Outcome Measure
Time Frame
correlation of specific striatal uptake to non specific uptake ratio of F-18 FPCIT and clinical sererity (H&Y stage)
Time Frame: 10 days
10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Asan Medical Center

Investigators

  • Principal Investigator: Jae Seung Kim, MD, Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2006

Primary Completion (Actual)

September 1, 2007

Study Completion (Actual)

October 1, 2007

Study Registration Dates

First Submitted

April 30, 2007

First Submitted That Met QC Criteria

April 30, 2007

First Posted (Estimate)

May 1, 2007

Study Record Updates

Last Update Posted (Estimate)

January 13, 2016

Last Update Submitted That Met QC Criteria

January 11, 2016

Last Verified

January 1, 2016

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FPCITKR001

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson's Disease

Clinical Trials on PET/CT

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe